We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Triamcinolone or Bevacizumab for Central Retinal Vein Occlusion With Poor Vision

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01053858
First Posted: January 22, 2010
Last Update Posted: January 22, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Hallym University Medical Center
January 14, 2010
January 22, 2010
January 22, 2010
January 2008
January 2009   (Final data collection date for primary outcome measure)
best corrected visual acuity [ Time Frame: baseline, 1 month, 2 months, 3 months, 6 months, 12 months ]
Same as current
No Changes Posted
central macular thickness by optical coherence tomography [ Time Frame: baseline, 1 month, 2 months, 3 months, 6 months 12months ]
Same as current
Not Provided
Not Provided
 
Triamcinolone or Bevacizumab for Central Retinal Vein Occlusion With Poor Vision
Not Provided
To evaluate the effect of intravitreal bevacizumab with intravitreal triamcinolone for the treatment of central retinal vein occlusion (CRVO) presenting poor visual acuity.
Not Provided
Interventional
Not Provided
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Central Retinal Vein Occlusion With 20/200 or Worse Visual Acuity
Procedure: intravitreal injection
intravitreal bevacizumab( 1.25 mg) or triamcinolone( 4mg) injection
  • Active Comparator: bevacizumab
    intravitreal bevacizumab or triamcinolone determined by single physician
    Intervention: Procedure: intravitreal injection
  • Active Comparator: triamcinolone
    Intervention: Procedure: intravitreal injection
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
38
January 2010
January 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • central macular thickness of more than 250 μm and baseline visual acuity of 20/200 or worse than 20/200 in patient with central retinal vein occlusion

Exclusion Criteria:

  • previous treatment such as intravitreal injection, subtenon injection, or laser photocoagulation since the time of onset
  • Patients with a history of glaucoma, neovascular glaucoma, diabetic retinopathy, and macular disorders
  • neovascularization on the disc or elsewhere or rubeosis
Sexes Eligible for Study: All
20 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
 
NCT01053858
2009_10_12
Yes
Not Provided
Not Provided
Not Provided
Hallym University Medical Center
Not Provided
Not Provided
Hallym University Medical Center
January 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP